1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial

 
• By Alaric DeArment

The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.

Nordic Nanovector plans to restructure after discontinuing its NHL trial, PARADIGME • Source: Shutterstock

Nordic Nanovector ASA is angling to partner out the radioimmunoconjugate candidate Betalutin (177Lu lilotomab satetraxetan) as it plans to restructure following a negative interim analysis that led to the discontinuation of the Phase IIb PARADIGME trial of the drug in third-line follicular lymphoma (FL). The program had already faced recruitment challenges, and the company plans to focus its efforts on other assets in its pipeline as it seeks to reduce costs.

The Norway-based biotech said 5 July that it had chosen to discontinue PARADIGME following a comprehensive review and independent data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Pipeline Watch: Five Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

More from R&D